Mga Batayang Estadistika
| LEI | 5299005F094GH9QDDD80 |
| CIK | 1358762 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Reata Pharmaceuticals Inc - Class A
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-37785 Reata Pharmaceuticals, Inc. (Exact name of registrant as specified |
|
| September 28, 2023 |
RETA / Reata Pharmaceuticals Inc - Class A / CPMG Inc - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 16)* Reata Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 75615P103 (CUSIP Number) John Bateman CPMG, Inc. 4215 West Lovers Lane, Suite 100 Dallas, Texas 75209 214-871-6816 (Name, Addres |
|
| September 28, 2023 |
RETA / Reata Pharmaceuticals Inc - Class A / BIOGEN INC. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 1)* Under the Securities Exchange Act of 1934 REATA PHARMACEUTICALS, INC. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 75615P 103 (CUSIP Number) Biogen Inc. 225 Binney Street Cambridge, Massachusetts 02142 (617) 679-2000 Attention: Wende |
|
| September 26, 2023 |
Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF Reata Pharmaceuticals, Inc. (a Delaware Corporation) ARTICLE ONE The name of the corporation (hereinafter called the “Corporation”) is Reata Pharmaceuticals, Inc. ARTICLE TWO The address, including street, number, city, and county, of the registered office of the Corporation in the State of Delaware is 3411 Silverside Road Rodney Bui |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) DELAWARE 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 26, 2023 |
Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF REATA PHARMACEUTICALS, INC. Effective as of September 26, 2023 ARTICLE I Meetings of Stockholders; Stockholders’ Consent in Lieu of Meeting SECTION 1.01. Annual Meeting. The annual meeting of the stockholders for the election of directors, and for the transaction of such other business as may properly come before the meeting, shall be held at such place, |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. |
|
| September 26, 2023 |
Exhibit 3.4 AMENDED AND RESTATED BY-LAWS OF REATA PHARMACEUTICALS, INC. Effective as of September 26, 2023 ARTICLE I Meetings of Stockholders; Stockholders’ Consent in Lieu of Meeting SECTION 1.01. Annual Meeting. The annual meeting of the stockholders for the election of directors, and for the transaction of such other business as may properly come before the meeting, shall be held at such place, |
|
| September 26, 2023 |
RETA / Reata Pharmaceuticals Inc - Class A / ROSE WILLIAM - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. |
|
| September 26, 2023 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF Reata Pharmaceuticals, Inc. (a Delaware Corporation) ARTICLE ONE The name of the corporation (hereinafter called the “Corporation”) is Reata Pharmaceuticals, Inc. ARTICLE TWO The address, including street, number, city, and county, of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, Wilmington, |
|
| September 21, 2023 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) DELAWARE 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 21, 2023 |
Exhibit 99.1 REATA PHARMACEUTICALS STOCKHOLDERS APPROVE MERGER TRANSACTION WITH BIOGEN INC. PLANO, Texas—September 21, 2023 (BUSINESS WIRE)—Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that at a special meeting held |
|
| September 19, 2023 |
JOINDER TO VOTING AND SUPPORT AGREEMENT EX-7.9 3 d551748dex79.htm EX-7.9 Exhibit 7.9 JOINDER TO VOTING AND SUPPORT AGREEMENT This JOINDER TO VOTING AND SUPPORT AGREEMENT is dated as of September 14, 2023 (this “Joinder”), by the Charles Henry Rose 2001 Trust, a Texas trust (the “Joining Holder”), in connection with that certain Voting and Support Agreement, dated as of July 28, 2023 (the “Voting and Support Agreement”), by and among Wil |
|
| September 19, 2023 |
RETA / Reata Pharmaceuticals Inc - Class A / ROSE WILLIAM - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 19, 2023 |
JOINDER TO VOTING AND SUPPORT AGREEMENT EX-7.8 2 d551748dex78.htm EX-7.8 Exhibit 7.8 JOINDER TO VOTING AND SUPPORT AGREEMENT This JOINDER TO VOTING AND SUPPORT AGREEMENT is dated as of September 14, 2023 (this “Joinder”), by the Edward Alexander Rose 1999 Trust, a Texas trust (the “Joining Holder”), in connection with that certain Voting and Support Agreement, dated as of July 28, 2023 (the “Voting and Support Agreement”), by and among |
|
| September 19, 2023 |
THIRD AMENDED AND RESTATED JOINT FILING AGREEMENT EX-99.3 5 d551748dex993.htm EX-99.3 Exhibit 99.3 THIRD AMENDED AND RESTATED JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1)(iii) of the Securities Exchange Act of 1934, as amended, each of the undersigned hereby consent to the joint filing on its behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of the shares of Clas |
|
| September 19, 2023 |
JOINDER TO VOTING AND SUPPORT AGREEMENT EX-7.10 4 d551748dex710.htm EX-7.10 Exhibit 7.10 JOINDER TO VOTING AND SUPPORT AGREEMENT This JOINDER TO VOTING AND SUPPORT AGREEMENT is dated as of September 14, 2023 (this “Joinder”), by the John William Rose 2002 Trust, a Texas trust (the “Joining Holder”), in connection with that certain Voting and Support Agreement, dated as of July 28, 2023 (the “Voting and Support Agreement”), by and among |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) DELAWARE 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) DELAWARE 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 24, 2023 |
SECOND AMENDED AND RESTATED JOINT FILING AGREEMENT EX-99.2 3 d526488dex992.htm EX-99.2 Exhibit 99.2 SECOND AMENDED AND RESTATED JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1)(iii) of the Securities Exchange Act of 1934, as amended, each of the undersigned hereby consent to the joint filing on its behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of the shares of Cla |
|
| August 24, 2023 |
JOINDER TO VOTING AND SUPPORT AGREEMENT EX-7.7 Exhibit 7.7 JOINDER TO VOTING AND SUPPORT AGREEMENT This JOINDER TO VOTING AND SUPPORT AGREEMENT is dated as of August 23, 2023 (this “Joinder”), by The Rose Family Foundation, a Texas nonprofit corporation (the “Joining Holder”), in connection with that certain Voting and Support Agreement, dated as of July 28, 2023 (the “Voting and Support Agreement”), by and among William E. Rose, Evelyn |
|
| August 24, 2023 |
RETA / Reata Pharmaceuticals Inc - Class A / ROSE WILLIAM - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 22, 2023 |
DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 11, 2023 |
PREM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 11, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) REATA PHARMACEUTICALS, INC. |
|
| August 8, 2023 |
Exhibit 10.4 SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE AGREEMENT (this “Amendment”) is made and entered into as of this 19 day of June, 2023, by and between TC LEGACY PHASE I VENTURE, LLC, a Delaware limited liability company (“Landlord”), and REATA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant entered into a certain Lease Agreem |
|
| August 8, 2023 |
Exhibit 10.7 TERMINATION OF EXPANSION AGREEMENT THIS TERMINATION OF EXPANSION AGREEMENT (this “Termination”) is executed by TC LEGACY LAND VENTURE, LLC, a Delaware limited liability company (“Owner”), and REATA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). RECITALS A. Owner and Tenant are parties to a certain Expansion Agreement dated October 15, 2019 (the “Expansion Agreement”). The E |
|
| August 8, 2023 |
Indemnification Agreement by and between the Company and Rajiv Patni, dated as of June 12 2023. Exhibit 10.5 REATA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT This Agreement (“Agreement”) is made and entered into as of the 12th day of June, 2023, by and between Reata Pharmaceuticals, a Delaware corporation (the “Company”), and Rajiv Patni (“Indemnitee”). RECITALS A. Highly competent and experienced persons are reluctant to serve corporations as directors, executive officers or in other c |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37785 Reata Pharmaceuticals, Inc. |
|
| August 8, 2023 |
Employment Agreement by and between the Company and Rajiv Patni, dated as of June 12, 2023. Exhibit 10.6 EMPLOYMENT AGREEMENT by and between Reata Pharmaceuticals, Inc. and Rajiv Patni THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of June 12, 2023 by and between Reata Pharmaceuticals, Inc., a Delaware corporation (together with its successors and assigns permitted hereunder, the “Company”), and Rajiv Patni (the “Executive”). NOW, THEREFORE, IT IS HEREBY AGREED A |
|
| August 7, 2023 |
RETA / Reata Pharmaceuticals Inc - Class A / BIOGEN INC. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 REATA PHARMACEUTICALS, INC. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 75615P 103 (CUSIP Number) Biogen Inc. 225 Binney Street Cambridge, Massachusetts 02142 (617) 679-2000 Attention: Wendell Taylor, Assistant Se |
|
| August 1, 2023 |
RETA / Reata Pharmaceuticals Inc - Class A / CPMG Inc - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 15)* Reata Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 75615P103 (CUSIP Number) John Bateman CPMG, Inc. 4215 West Lovers Lane, Suite 100 Dallas, Texas 75209 214-871-6816 (Name, Addres |
|
| July 31, 2023 |
EX-99.3 Exhibit 99.3 VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT is dated as of July 28, 2023 (this “Agreement”), by and among each stockholder of Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), set forth on Exhibit A hereto (each a “Holder” and collectively the “Holders”), Biogen Inc., a Delaware corporation (“Parent”), and River Acquisition, Inc., a Delawa |
|
| July 31, 2023 |
EX-99.1 Exhibit 99.1 VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT is dated as of July 28, 2023 (this “Agreement”), by and among each stockholder of Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), set forth on Exhibit A hereto (each a “Holder” and collectively the “Holders”), Biogen Inc., a Delaware corporation (“Parent”), and River Acquisition, Inc., a Delawa |
|
| July 31, 2023 |
EX-99.2 Exhibit 99.2 VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT is dated as of July 28, 2023 (this “Agreement”), by and among each stockholder of Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), set forth on Exhibit A hereto (each a “Holder” and collectively the “Holders”), Biogen Inc., a Delaware corporation (“Parent”), and River Acquisition, Inc., a Delawa |
|
| July 31, 2023 |
RETA / Reata Pharmaceuticals Inc - Class A / ROSE WILLIAM - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| July 31, 2023 |
EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among REATA PHARMACEUTICALS, INC., BIOGEN INC. and RIVER ACQUISITION, INC. Dated as of July 28, 2023 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 1.1 Certain Definitions 2 1.2 Additional Definitions 13 1.3 Certain Interpretations 15 ARTICLE II THE MERGER 2.1 The Merger 16 2.2 The Effective Time 16 2.3 The Cl |
|
| July 31, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) DELAWARE 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) ( |
|
| July 31, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) DELAWARE 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 28, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) DELAWARE 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) ( |
|
| July 28, 2023 |
EX-99.1 Exhibit 99.1 Biogen to Acquire Reata Pharmaceuticals SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical need Expected to be significantly accretive to Biog |
|
| July 28, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as per |
|
| July 28, 2023 |
Joint Press Release issued by Biogen Inc. and Reata Pharmaceuticals, Inc., dated July 28, 2023. EX-99.1 Exhibit 99.1 Biogen to Acquire Reata Pharmaceuticals SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical need Expected to be significantly accretive to Biog |
|
| July 28, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as per |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) DELAWARE 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 26, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Reata Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 75615P103 (CUSIP Number) June 16, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 (June 19, 2023) Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorpor |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) Reata Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 75615P103 (CUSIP Number) May 12, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| May 10, 2023 |
Exhibit 10.2 LOAN AGREEMENT Dated as of May 5, 2023 among REATA PHARMACEUTICALS, INC. (as Borrower, and a Credit Party), THE GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional Credit Parties), BIOPHARMA CREDIT PLC (as Collateral Agent), BPCR LIMITED PARTNERSHIP (as a Lender) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP (as a Lender) Table of Contents Page 1 AC |
|
| May 10, 2023 |
Exhibit 10.3 AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION FUNDING AGREEMENT This Amended and Restated Development and Commercialization Funding Agreement (this “Agreement”), made effective as of May 4, 2023 (the “Effective Date”), is by and between Reata Pharmaceuticals Inc., a Delaware corporation (“Reata”), and BXLS V – River L.P. (together with its successors and assigns, “BXLS”), a l |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 10, 2023 |
l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37785 Reata Pharmaceuticals, Inc. |
|
| May 10, 2023 |
Exhibit 10.1 AMENDMENT NO. 2 TO EXCLUSIVE LICENSE AGREEMENT This Amendment No. 2 (this “Amendment #2”) to the Exclusive License Agreement, dated as of September 26, 2014 and amended as of April 5, 2022 (the “License Agreement”), by and between the KU CENTER FOR TECHNOLOGY COMMERCIALIZATION, INC., a Kansas non-profit §501 (c)(3) corporation, having its principal place of business at 3901 Rainbow Bo |
|
| May 10, 2023 |
Exhibit 99.1 REATA PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON OPERATIONAL PROGRESS AND CLINICAL DEVELOPMENT PROGRAMS SKYCLARYS® APPROVED BY FDA IN THE U.S. APPROXIMATELY 500 PATIENT START FORMS RECEIVED FOR SKYCLARYS MARKETING AUTHORIZATION APPLICATION FOR OMAVELOXOLONE IN EUROPE UNDER REVIEW ANNOUNCED $275 MILLION DEBT FACILITY AND EXTENDED CASH |
|
| May 10, 2023 |
1st Quarter 2023 Financial Results and Update on Operational Progress and Development Programs May 10, 2023 Exhibit 99. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 7, 2023 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: March 7, 2023 PERCEPTIVE ADVISORS LLC By: |
|
| March 7, 2023 |
RETA / Reata Pharmaceuticals Inc - Class A / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Reata Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value per share (Title of Class of Securities) 75615P103 (CUSIP Number) March 6, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| March 2, 2023 |
Calculation of Filing Fee Tables. Exhibit 107.1 CALCULATION OF FILING FEE TABLES Form S-8 Registration Statement Under The Securities Act Of 1933 (Form Type) Reata Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule (2) Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 As filed with the Securities and Exchange Commission on March 2, 2023 Registration No. |
|
| March 1, 2023 |
Third Amended and Restated Bylaws, dated as of March 1, 2023. Exhibit 3.1 THIRD AMENDED AND RESTATED BYLAWS OF REATA PHARMACEUTICALS, INC. Effective as of March 1, 2023 Preamble These bylaws are subject to, and governed by, the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”) and the certificate of incorporation (as the same may be amended from time to time, the “Certificate of Incorporation”) of Reata Pharmaceuticals |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 28, 2023 |
Exhibit 99.2 REATA PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SKYCLARYS™ (OMAVALOXOLONE), THE FIRST AND ONLY DRUG INDICATED FOR PATIENTS WITH FRIEDREICH’S ATAXIA Friedreich’s Ataxia is an Ultra-Rare, Progressive, Neuromuscular disease that affects approximately 5,000 diagnosed patients in the United States SKYCLARYS is indicated for the treatment of Friedreich’s ataxia in adults and adolescents age |
|
| February 28, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 28, 2023 |
Reata Pharmaceuticals SKYCLARYS™ (Omaveloxolone) Approval Conference Call Script February 28, 2023 Exhibit 99.1 Reata Pharmaceuticals SKYCLARYS™ (Omaveloxolone) Approval Conference Call Script February 28, 2023 Company Participants Warren Huff – Chief Executive Officer Manmeet Soni – President, COO, CFO Colin Meyer – Chief Innovation Officer Seemi Khan – Chief Medical Officer Dawn Bir – Chief Commercial Officer Operator Script Thank you for standing by, and welcome to the Reata Pharmaceuticals |
|
| February 28, 2023 |
SKYCLARYS™ Approval Call February 28, 2023 Exhibit 99.3 This presentation contains certain “forward‐looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward‐looking statements, including statements regarding our future financial condition, futur |
|
| February 24, 2023 |
Seventh Amended and Restated Non-Employee Director Compensation Policy, dated as of June 8, 2022. Exhibit 10.53 REATA PHARMACEUTICALS, INC. SEVENTH AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of Reata Pharmaceuticals, Inc. (“Reata”) who is not also serving as an employee of or consultant to Reata or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Seventh Ame |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37785 Reata Pharmaceu |
|
| February 24, 2023 |
EXHIBIT 10.54 REATA PHARMACEUTICALS, INC. EIGHTH AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of Reata Pharmaceuticals, Inc. (“Reata”) who is not also serving as an employee of or consultant to Reata or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Eighth Amend |
|
| February 24, 2023 |
Exhibit 21.1 Subsidiaries of the Company Subsidiaries State or Jurisdiction Reata Pharmaceuticals Holdings, LLC United States Reata Pharmaceuticals Global, Inc. United States Reata Swiss International GmbH Switzerland Reata UK Ltd United Kingdom Reata Australia Pty Limited Australia Reata Ireland Limited Ireland Reata France SAS France Reata Italy S.r.l. Ireland Youco F23-H100 Vorrats-GmbH Germany |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) Reata Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 75615P103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 14, 2023 |
SC 13G/A 1 pt7213gaa.htm SCHEDULE 13G/A, AMENDMENT #1 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Reata Pharmaceuticals, Inc. (Ti |
|
| February 14, 2023 |
EX-99.1 2 pt7213gab.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf |
|
| February 10, 2023 |
RETA / Reata Pharmaceuticals Inc / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 reata13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Reata Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 75615P103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 9, 2023 |
RETA / Reata Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Reata Pharmaceuticals Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 75615P103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Sched |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 8, 2022 |
EX-99.2 3 reta-ex992.htm EX-99.2 3rd Quarter 2022 Financial Results and Update on Development Programs November 8, 2022 Exhibit 99.2 This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking sta |
|
| November 8, 2022 |
Exhibit 99.1 REATA PHARMACEUTICALS, INC. ANNOUNCES third QUARTER 2022 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL DEVELOPMENT PROGRAMS NDA FOR OMAVELOXOLONE FOR PATIENTS WITH FRIEDREICH’S ATAXIA UNDER REVIEW WITH PDUFA DATE OF FEBRUARY 28, 2023 FDA DOES NOT PLAN TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS THE OMAVELOXOLONE NDA AND THE LATE CYCLE MEETING HAS BEEN COMPLETED PROVIDES UP |
|
| November 8, 2022 |
l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37785 Reata Pharmaceuticals, Inc. |
|
| November 7, 2022 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE Exhibit 99.1 EFiled: Oct 12 2022 02:29PM EDT Transaction ID 682 Exhibit44491 Case No. 2022-0400-LWW IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE JOHN SOLAK, derivatively on behalf of REATA PHARMACEUTICALS, INC., Plaintiff, v. J. WARREN HUFF, MARTIN W. EDWARDS, M.D., WILLIAM D. MCCLELLAN, JR., R. KENT MCGAUGHY, JR., JACK B. NIELSEN, CHRISTY J. OLIGER, WILLIAM E. ROSE and SHAMIM RUFF, Defendant |
|
| November 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 5, 2022 |
Exhibit 4.3 REATA PHARMACEUTICALS, iNC. 2022 EMPLOYEE STOCK PURCHASE PLAN Article I Purpose, Share Commitment and Intent 1.1 Purpose. The purpose of the Reata Pharmaceuticals, Inc. 2022 Employee Stock Purchase Plan is to provide Employees of Reata Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and its Related Corporations that are selected by the Company to participate in the Plan |
|
| October 5, 2022 |
As filed with the Securities and Exchange Commission on October 5, 2022 As filed with the Securities and Exchange Commission on October 5, 2022 Registration No. |
|
| October 5, 2022 |
Calculation of Filing Fee Tables. Exhibit 107.1 CALCULATION OF FILING FEE TABLES Form S-8 Registration Statement Under The Securities Act Of 1933 (Form Type) Reata Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule (3) Amount Registered Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Pric |
|
| September 22, 2022 |
RETA / Reata Pharmaceuticals Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Reata Pharmaceuticals, Inc. (Title of Class of Securities) Class A Common Stock, Par Va |
|
| September 22, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* REATA PHARMACEUTICALS INC (Name of Issuer) Common Stock (Title of Class of Securities) 75615P103 (CUSIP Number) August 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| August 8, 2022 |
Exhibit 10.3 REATA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT This Agreement (?Agreement?) is made and entered into as of July 11, 2022, by and between Reata Pharmaceuticals, a Delaware corporation (the ?Company?), and Steven W. Ryder, M.D. (?Indemnitee?). RECITALS A. Highly competent and experienced persons are reluctant to serve corporations as directors, executive officers or in other capa |
|
| August 8, 2022 |
Exhibit 10.2 SEVENTH SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study in Japan This Seventh Supplement (herein so called), effective as of February 28, 2022 (the ?Supplement Effective Date?), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the ?Original Agreement?), is by and between Reata Pharmaceuticals Holdings, LLC, a limit |
|
| August 8, 2022 |
1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37785 Reata Pharmaceuticals, Inc. |
|
| August 8, 2022 |
2nd Quarter 2022 Financial Results and Update on Clinical Development Programs August 8, 2022 Exhibit 99. |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 8, 2022 |
Exhibit 99.1 REATA PHARMACEUTICALS, INC. ANNOUNCES Second QUARTER 2022 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL DEVELOPMENT PROGRAMS RECEIVED PRIORITY REVIEW AND ACCEPTANCE FOR FILING OF THE NDA FOR OMAVELOXOLONE FOR TREATMENT OF PATIENTS WITH FRIEDREICH?S ATAXIA PROVIDES UPDATE FROM FDA MID-CYCLE COMMUNICATION MEETING ON OMAVELOXOLONE FOR PATIENTS WITH FRIEDREICH?S ATAXIA ANNOUNCES RE |
|
| July 12, 2022 |
Indemnification Agreement by and between the Company and Steven W. Ryder, dated as of July 11, 2022. Exhibit 10.1 REATA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT This Agreement (?Agreement?) is made and entered into as of July 11, 2022, by and between Reata Pharmaceuticals, a Delaware corporation (the ?Company?), and Steven W. Ryder, M.D. (?Indemnitee?). RECITALS A. Highly competent and experienced persons are reluctant to serve corporations as directors, executive officers or in other capa |
|
| July 12, 2022 |
Exhibit 99.1 Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors PLANO, Texas?July 11, 2022 (BUSINESS WIRE)?Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (?Reata,? the ?Company,? or ?we?), a clinical-stage biopharmaceutical company, today announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022. ?We are thrilled to welcome Dr |
|
| July 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2022 (July 11, 2022) Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorpor |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 (June 8, 2022) Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporat |
|
| May 10, 2022 |
1st Quarter 2022 Financial Results and Update on Clinical Development Programs May 10, 2022 Exhibit 99. |
|
| May 10, 2022 |
Exhibit 10.1 AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENT This Amendment No. 1 (this ?Amendment #1?) to the Exclusive License Agreement, dated as of September 26, 2014 (the ?License Agreement?), by and between the KU CENTER FOR TECHNOLOGY COMMERCIALIZATION, INC., a Kansas non-profit ?501 (c)(3) corporation, having its principal place of business at 3901 Rainbow Boulevard, Kansas City, Kansas 661 |
|
| May 10, 2022 |
Exhibit 10.2 SEVENTH SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study in Japan This Seventh Supplement (herein so called), effective as of February 28, 2022 (the ?Supplement Effective Date?), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the ?Original Agreement?), is by and between Reata Pharmaceuticals Holdings, LLC, a limit |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37785 Reata Pharmaceuticals, Inc. |
|
| May 10, 2022 |
Exhibit 99.1 REATA PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL DEVELOPMENT PROGRAMS COMPLETED ROLLING SUBMISSION OF NDA FOR OMAVELOXOLONE FOR TREATMENT OF PATIENTS WITH FRIEDREICH?S ATAXIA; ACTIVELY PREPARING FOR COMMERCIAL LAUNCH UPDATES OUTCOME OF TYPE A MEETING WITH THE FDA ON THE PROTOCOL AMENDMENT FOR FALCON; FDA CONFIRMS WEEK 108 AS |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 11, 2022 |
RETA / Reata Pharmaceuticals Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Reata Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 75615P103 (CUSIP Number) March 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| March 18, 2022 |
As filed with the Securities and Exchange Commission on March 18, 2022 As filed with the Securities and Exchange Commission on March 18, 2022 Registration No. |
|
| March 18, 2022 |
Calculation of Filing Fee Tables. Exhibit 107.1 CALCULATION OF FILING FEE TABLES Form S-8 Registration Statement Under The Securities Act Of 1933 (Form Type) Reata Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule (2) Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering P |
|
| March 10, 2022 |
RETA / Reata Pharmaceuticals Inc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Reata Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 75615P103 (CUSIP Number) February 28, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 (March 1, 2022) Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorpor |
|
| February 28, 2022 |
4th Quarter and Full Year 2021 Financial Results and Update on Clinical Development Programs February 28, 2022 Exhibit 99. |
|
| February 28, 2022 |
Exhibit 10.26 Specific terms in this Exhibit have been redacted because such terms are both not material and are of the type that the Company treats as private or confidential. These redacted terms have been marked in this Exhibit with three asterisks [***]. EXCLUSIVE LICENSE AGREEMENT between Reata Pharmaceuticals, Inc. and KU Center for Technology Commercialization, Inc. Exclusive License Agreem |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 28, 2022 |
Indemnification Agreement by and between the Company and Samina Khan, dated as of February 24, 2020. Exhibit 10.13 REATA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT This Agreement (?Agreement?) is made and entered into as of the 7th day of July, 2020, by and between Reata Pharmaceuticals, a Delaware corporation (the ?Company?), and Samina Khan (?Indemnitee?). RECITALS A. Highly competent and experienced persons are reluctant to serve corporations as directors, executive officers or in other c |
|
| February 28, 2022 |
Exhibit 21.1 Subsidiaries of the Company Subsidiaries State or Jurisdiction Reata Pharmaceuticals Holdings, LLC United States Reata Pharmaceuticals Global, Inc. United States Reata Swiss International GmbH Switzerland Reata UK Ltd United Kingdom Reata Australia Pty Limited Australia Reata Ireland Limited Ireland Reata Confidential |
|
| February 28, 2022 |
Exhibit 10.31 FOURTH SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Milestone payments, Supply price and Products manufacturing This Fourth Supplement (herein so called), effective as of December 6, 2017 (the ?Supplement Effective Date?), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the ?Original Agreement?), is by and between Reata Pharmaceutic |
|
| February 28, 2022 |
Exhibit 10.28 Specific terms in this Exhibit have been redacted because such terms are both not material and are of the type that the Company treats as private or confidential. These redacted terms have been marked in this Exhibit with three asterisks [***]. LICENSE AGREEMENT between REATA PHARMACEUTICALS, INC. and ABBOTT PHARMACEUTICALS PR LTD. Dated as of September 21, 2010 TABLE OF CONTENTS ART |
|
| February 28, 2022 |
Notice of Grant of Restricted Stock Units for employees, dated as of December 3, 2021. Exhibit 10.48 Date Notice of Grant of Restricted Stock Units (Employee) Award Details Name : Address : Employee ID : Award Amount : Grant ID : Date of Grant: Award Type : Vesting Schedule : Vesting Start Date : Vesting End Date : Expiration Date : Deadline to Accept : 30 days from grant notification Award Vesting Summary The Forfeiture Restrictions on the Restricted Stock Units granted pursuant to |
|
| February 28, 2022 |
Sixth Amended and Restated Non-Employee Director Compensation Policy, dates as of December 17, 2021. Exhibit 10.50 Pursuant to Section 141(f) of the General Corporation Law of the State of Delaware and the authority contained in Article III, Section 3.10 of the Second Amended and Restated Bylaws of Reata Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), the undersigned, being all the members of the Board of Directors of the Company (the ?Board?), hereby consent to the adoption of, an |
|
| February 28, 2022 |
Exhibit 10.30 THIRD SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study (Alport Syndrome) in Japan This Third Supplement (herein so called), effective as of December 6, 2017 (the ?Supplement Effective Date?), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the ?Original Agreement?), is by and between Reata Pharmaceuticals, Inc., a |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37785 Reata Pharmaceu |
|
| February 28, 2022 |
Employment Agreement by and between the Company and Andrea Loewen, dated as of February 24, 2020. Exhibit 10.16 EMPLOYMENT AGREEMENT by and between Reata Pharmaceuticals, Inc. and Andrea Loewen-Rodriguez THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into as of the 24th day February of 2020, by and between Reata Pharmaceuticals, Inc., a Delaware corporation (together with its successors and assigns permitted hereunder, the ?Company?), and Andrea Loewen-Rodriguez (the ?Executiv |
|
| February 28, 2022 |
EX-99.1 2 reta-ex9917.htm EX-99.1PR Exhibit 99.1 REATA PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL DEVELOPMENT PROGRAMS INITIATED ROLLING SUBMISSION OF NDA FOR OMAVELOXOLONE FOR TREATMENT OF PATIENTS WITH FRIEDREICH’S ATAXIA; ACTIVELY PREPARING FOR COMMERCIAL LAUNCH UPDATED CASH GUIDANCE - SUFFICIENT TO FUND OPERATIONS THRO |
|
| February 28, 2022 |
Employment Agreement by and between the Company and Samina Khan, dated as of July 7, 2020. Exhibit 10.15 EMPLOYMENT AGREEMENT by and between Reata Pharmaceuticals, Inc. and Samina Khan THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into as of the 7th day July of 2020, by and between Reata Pharmaceuticals, Inc., a Delaware corporation (together with its successors and assigns permitted hereunder, the ?Company?), and Samina Khan (the ?Executive?). NOW, THEREFORE, IT IS HE |
|
| February 28, 2022 |
Exhibit 10.25 SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH THREE ASTERISKS [***]. REATA PHARMACEUTICALS, INC. DARTMOUTH EXCLUSIVE LICENSE AGREEMENT This Agreement, effective this 16th day of December 2009, between TRUSTEES OF DARTMOUTH COLLEGE, a non-profit educational |
|
| February 28, 2022 |
Exhibit 10.38 LEASE AMENDMENT NO. 13 THIS LEASE AMENDMENT NO. 13 (this ?Amendment?) is made and entered into effective as of February 4, 2022 (the ?Effective Date?) by and between SDCO GATEWAY COMMERCE I & II, INC., a Delaware corporation (?Landlord?), and REATA PHARMACEUTICALS, INC., a Delaware corporation (?Tenant?). Recitals: WHEREAS, by Lease dated with a Lease Reference Date as of May 25, 200 |
|
| February 28, 2022 |
Exhibit 10.49 Date Notice of Grant of Restricted Stock Units (Directors/Consultants) Award Details Name : Address : Employee ID : Award Amount : Grant ID : Date of Grant: Award Type : Vesting Schedule : Expiration Date : Deadline to Accept : 30 days from grant notification Award Vesting Summary The Forfeiture Restrictions on the Restricted Stock Units granted pursuant to the Restricted Stock Unit |
|
| February 28, 2022 |
Exhibit 10.24 Specific terms in this Exhibit have been redacted because such terms are both not material and are of the type that the Company treats as private or confidential. These redacted terms have been marked in this Exhibit with three asterisks [***]. EXCLUSIVE PATENT LICENSE AGREEMENT AMONG THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER DARTMOUTH COLLEGE AND REATA DISCOVERY, INC. Spe |
|
| February 28, 2022 |
Exhibit 10.27 Specific terms in this Exhibit have been redacted because such terms are both not material and are of the type that the Company treats as private or confidential. These redacted terms have been marked in this Exhibit with three asterisks [***]. Execution Version EXCLUSIVE LICENSE and SUPPLY AGREEMENT by and between REATA PHARMACEUTICALS, INC. and KYOWA HAKKO KIRIN CO. LTD. Execution |
|
| February 28, 2022 |
Exhibit 10.14 REATA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT This Agreement (?Agreement?) is made and entered into as of the 24th day of February, 2020, by and between Reata Pharmaceuticals, a Delaware corporation (the ?Company?), and Andrea Loewen-Rodriguez (?Indemnitee?). RECITALS A. Highly competent and experienced persons are reluctant to serve corporations as directors, executive offic |
|
| February 28, 2022 |
Exhibit 10.29 Specific terms in this Exhibit have been redacted because such terms are both not material and are of the type that the Company treats as private or confidential. These redacted terms have been marked in this Exhibit with three asterisks [***]. EXECUTION COPY COLLABORATION AGREEMENT between REATA PHARMACEUTICALS, INC. and ABBOTT PHARMACEUTICALS PR LTD. Dated as of December 9, 2011 TA |
|
| February 10, 2022 |
RETA / Reata Pharmaceuticals Inc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Reata Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 75615P103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 10, 2022 |
RETA / Reata Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01761-reatapharmaceuticals.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Reata Pharmaceuticals Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 75615P103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropr |
|
| February 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2022 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* REATA PHARMACEUTICALS INC (Name of Issuer) Common Stock (Title of Class of Securities) 75615P103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| November 8, 2021 |
Exhibit 10.2 AMENDMENT NO. 2 TO 2009 LICENSE AGREEMENT Amendment No. 2, dated as of August 17, 2021 (this ?Amendment?), to the Reata Pharmaceuticals, Inc. - Dartmouth Exclusive License Agreement, effective December 16, 2009, as amended by the Amendment No. 1 to 2009 License Agreement dated as of July 9, 2012 (as so amended, the ?License Agreement?), by and between Trustees of Dartmouth College (?D |
|
| November 8, 2021 |
November 8, 2021 3rd Quarter 2021 Financial Results and Update on Clinical Development Programs Exhibit 99. |
|
| November 8, 2021 |
As filed with the Securities and Exchange Commission on November 8, 2021 Table of Contents As filed with the Securities and Exchange Commission on November 8, 2021 Registration No. |
|
| November 8, 2021 |
Exhibit 10.1 AMENDMENT NO. 2 TO 2004 LICENSE AGREEMENT Amendment No. 2, dated as of August 17, 2021 (this ?Amendment?), to the Exclusive Patent License Agreement, dated as of July 15, 2004, as amended by the Amendment effective as of April 11, 2007 and as further amended by the Amendment No. 1 to 2004 License Agreement dated as of July 9, 2012 (as so amended, excluding this Amendment, the ?License |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 8, 2021 |
Exhibit 99.1 REATA PHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL DEVELOPMENT PROGRAMS ADVISORY COMMITTEE MEETING for BARDOXOLONE FOR PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME scheduled FOR DECEMBER 8, 2021 SUBMITTED MAA TO THE EMA FOR BARDOXOLONE FOR PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME in OCTOBER 2021 PLANNED NDA submission for om |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37785 Reata Pharmaceuticals, Inc. |
|
| October 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2021 (October 18, 2021) Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of In |
|
| September 10, 2021 |
RETA / Reata Pharmaceuticals Inc / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Reata Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 75615P103 (CUSIP Number) August 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| August 20, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2021 (August 17, 2021) Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Inco |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 9, 2021 |
Exhibit 99.1 Reata pharmaceuticals, inc. announces SECOND quarter 2021 financial RESULTS and provides an update on CLINICAL DEVELOPMENT programs PRE-NDA MEETING WITH FDA SCHEDULED FOR Q3 2021 ON OMAVELOXOLONE FOR PATIENTS WITH FA AND REATA ANNOUNCES PLAN TO FILE OMAVELOXOLONE NDA DURING Q1 2022 PROVIDES UPDATE FROM MID-CYCLE COMMUNICATION MEETING ON BARDOXOLONE FOR PATIENTS WITH CKD CAUSED BY ALPO |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37785 Reata Pharmaceuticals, Inc. |
|
| August 9, 2021 |
August 9, 2021 2nd Quarter 2021 Financial Results and Update on Clinical Development Programs Exhibit 99. |
|
| June 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 (June 18, 2021) Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorpor |
|
| June 11, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 (June 10, 2021) Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorpor |
|
| May 6, 2021 |
Notice of Grant of Restricted Stock Units for employees, dated as of December 2, 2020 Exhibit 10.3 Date Notice of Grant of Restricted Stock Units (Employee) Award Details Name : Address : Employee ID : Award Amount : Grant ID : Date of Grant: Award Type : Vesting Schedule :Vesting Start Date :Vesting End Date :Expiration Date : Deadline to Accept : 30 days from grant notification Award Vesting Summary The Forfeiture Restrictions on the Restricted Stock Units granted pursuant to the |
|
| May 6, 2021 |
1st Quarter 2021 Financial Results and Update on Clinical Development Programs May 6, 2021 Exhibit 99. |
|
| May 6, 2021 |
Exhibit 99.1 Reata pharmaceuticals, inc. announces First quarter 2021 financial RESULTS and provides an update on CLINICAL DEVELOPMENT programs ANNOUNCES FDA ACCEPTED FOR FILING REATA?S NDA OF BARDOXOLONE FOR THE TREATMENT OF PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME IF APPROVED, BARDOXOLONE MAY BECOME THE FIRST APPROVED THERAPY FOR ALPORT SYNDROME, A LIFE-THREATENING DISEASE THAT AFFECTS 30,000 |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37785 Reata Pharmaceuticals, Inc. |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 15, 2021 |
Indemnification Agreement by and between the Company and Shamim Ruff, dated as of April 15, 2021. Exhibit 10.2 REATA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT This Agreement (?Agreement?) is made and entered into as of the 15th day of April, 2021, by and between Reata Pharmaceuticals, a Delaware corporation (the ?Company?), and Shamim Ruff (?Indemnitee?). RECITALS A. Highly competent and experienced persons are reluctant to serve corporations as directors, executive officers or in other |
|
| April 15, 2021 |
Exhibit 10.1 REATA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT This Agreement (?Agreement?) is made and entered into as of the 15th day of April, 2021, by and between Reata Pharmaceuticals, a Delaware corporation (the ?Company?), and Christy J. Oliger (?Indemnitee?). RECITALS A. Highly competent and experienced persons are reluctant to serve corporations as directors, executive officers or in |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2021 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 15, 2021 |
Exhibit 99.1 REATA Announces THE APPOINTMENTs OF Christy J. Oliger and Shamim Ruff TO ITS BOARD OF DIRECTORS PLANO, Texas?April 15, 2021 (GLOBE NEWSWIRE)?Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (?Reata,? the ?Company,? or ?we?), a clinical-stage biopharmaceutical company, today announced the appointments of Christy J. Oliger and Shamim Ruff to its Board of Directors, effective April 15, 2021. ? |
|
| March 15, 2021 |
As filed with the Securities and Exchange Commission on March 15, 2021 Registration No. |
|
| March 1, 2021 |
Notice of Grant of Restricted Stock Units for director/consultants, dated as of December 2, 2020 Exhibit 10.38 Date Notice of Grant of Restricted Stock Units (Directors/Consultants) Award Details Name : Address : Employee ID : Award Amount : Grant ID : Date of Grant: Award Type : Vesting Schedule : Expiration Date : Deadline to Accept : 30 days from grant notification Award Vesting Summary The Forfeiture Restrictions on the Restricted Stock Units granted pursuant to the Restricted Stock Unit |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37785 Reata Pharmaceu |
|
| March 1, 2021 |
Fifth Amended and Restated Non-Employee Director Compensation Policy, dated as of December 2, 2020. Exhibit 10.37 REATA PHARMACEUTICALS, INC. FIFTH AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Reata Pharmaceuticals, Inc. (?Reata?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Fifth Amended and Rest |
|
| March 1, 2021 |
4th Quarter and Full Year 2020 Financial Results and Update on Clinical Development Programs March 1, 2021 Exhibit 99. |
|
| March 1, 2021 |
Exhibit 99.1 Reata pharmaceuticals, inc. announces FOURTH quarter AND FULL YEAR 2020 financial RESULTS and provides an update on CLINICAL DEVELOPMENT programs ANNOUNCES FIRST NDA SUBMISSION FOR COMPANY?S LEAD PROGRAM: BARDOXOLONE IN ALPORT SYNDROME PROVIDES UPDATE ON FALCON STUDY OF BARDOXOLONE IN ADPKD ANNOUNCES FIRST PATIENT ENROLLED IN MERLIN TRIAL OF BARDOXOLONE IN CHRONIC KIDNEY DISEASE AT RI |
|
| March 1, 2021 |
Exhibit 21.1 Subsidiaries of the Company Subsidiaries State or Jurisdiction Reata Pharmaceuticals Holdings, LLC United States Reata Pharmaceuticals Global, Inc. United States Reata Swiss International GmbH Switzerland Reata UK Ltd United Kingdom Reata Australia Pty Limited Australia |
|
| February 16, 2021 |
Invesco Joint Filing Agreement JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Reata Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 75615P103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Reata Pharmaceuticals Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 75615P103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Sched |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* REATA PHARMACEUTICALS INC (Name of Issuer) Common Stock (Title of Class of Securities) 75615P103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| January 11, 2021 |
EX-99.1 2 reta-ex99121.htm EX-99.1 Investor Presentation JANUARY 2021 Exhibit 99.1 Forward-Looking Statements This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statements, including stat |
|
| January 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 14)* Reata Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 75615P103 (CUSIP Number) John Bateman CPMG, Inc. 2000 McKinney Ave, Suite 2125 Dallas, Texas 75201 214-871-6816 (Name, Address and Telep |
|
| December 9, 2020 |
Lock-Up Agreement Reata Pharmaceuticals, Inc. Public Offering of Common Stock EX-99.7.5 Exhibit 7.5 Lock-Up Agreement Reata Pharmaceuticals, Inc. Public Offering of Common Stock The Representative(s) of the Underwriters Named in Schedule II to the Underwriting Agreement Ladies and Gentlemen: This letter, dated as of the date set forth on the signature page hereto, is being delivered to you in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”) |
|
| December 9, 2020 |
Lock-Up Agreement Reata Pharmaceuticals, Inc. Public Offering of Common Stock EX-99.7.4 Exhibit 7.4 Lock-Up Agreement Reata Pharmaceuticals, Inc. Public Offering of Common Stock The Representative(s) of the Underwriters Named in Schedule II to the Underwriting Agreement Ladies and Gentlemen: This letter, dated as of the date set forth on the signature page hereto, is being delivered to you in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”) |
|
| December 9, 2020 |
RETA / Reata Pharmaceuticals, Inc. / ROSE WILLIAM - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 3, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in its Charter) DELAWARE 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 3, 2020 |
EX-1.1 Exhibit 1.1 Execution Version Reata Pharmaceuticals, Inc. 2,000,000 Shares Class A Common Stock ($0.001 par value per share) Underwriting Agreement New York, New York December 1, 2020 Barclays Capital Inc. Goldman Sachs & Co. LLC As Representatives of the several Underwriters, c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 Goldman Sachs & Co. LLC 200 West Street New Y |
|
| December 3, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-226289 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Class A common stock, $0.001 par value per share 2,300,000 $140.85 $323,955,000 $35,343.50 Total 2 |
|
| December 1, 2020 |
SUBJECT TO COMPLETION. DATED DECEMBER 1, 2020 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) SEC File No. 333-226289 The information in this prospectus supplement and the accompanying prospectus is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not offers to sell these securities, and we are not soliciting offers to buy these securities, in any jurisdiction where the offer or sale is |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37785 Reata Pharmaceuticals, Inc. |
|
| November 9, 2020 |
Exhibit 99.1 Reata pharmaceuticals, inc. announces Third quarter 2020 financial RESULTS and provides an update on BUSINESS OPERATIONS AND CLINICAL DEVELOPMENT programs Reported positive year 2 data from the pivotal CARDINAL study of bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome Reported long term efficacy data from EAGLE (open-label extension) study Reported |
|
| November 9, 2020 |
Management Call CARDINAL Year 2 Data EAGLE Year 3 Data MOXIe Baseline-Controlled Study Data Third Quarter 2020 Earnings NOV 9. |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 9, 2020 |
Exhibit 99.2 Reata announces positive results from year 2 of the pivotal phase 3 cardinal study of bardoxolone methyl in patients with alport syndrome BARDOXOLONE Achieved the year 2 primary and key secondary endpoints with statistically significant improvements in egfr AS COMPARED TO PLACEBO at week 100 and Week 104 BARDOXOLONE patients who remained on treatment had continued improvement Above ba |
|
| November 9, 2020 |
Reata Pharmaceuticals Inc. (Q3 Results) November 09, 2020 Exhibit 99.1 Transcript of earnings call held on November 9, 2020. Reata Pharmaceuticals Inc. (Q3 Results) November 09, 2020 Corporate Speakers: ? Vinny Jindal; Reata Pharmaceuticals Inc.; VP of Strategy ? Warren Huff; Reata Pharmaceuticals Inc.; CEO ? Colin Meyer; Reata Pharmaceuticals Inc.; Chief Research & Development Officer ? Manmeet Soni; Reata Pharmaceuticals Inc.; COO & CFO Participants: ? |
|
| November 9, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2020 (August 26, 2020) Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Inco |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 10, 2020 |
Exhibit 10.3 Execution Version DEVELOPMENT AND COMMERCIALIZATION FUNDING AGREEMENT This Development and Commercialization Funding Agreement (“Agreement”), made effective as of June 10, 2020 (the “Effective Date”), is by and between Reata Pharmaceuticals Inc., a Delaware corporation (“Reata”), and BXLS V – River L.P. (together with its successors and assigns, “BXLS”), a limited partnership organize |
|
| August 10, 2020 |
Exhibit 99.1 Reata pharmaceuticals, inc. announces SECOND quarter 2020 financial RESULTS and provides an update on BUSINESS OPERATIONS AND CLINICAL DEVELOPMENT programs PRE-NDA (NEW DRUG APPLICATION) MEETING GRANTED for Bardoxolone regulatory update on OMAVELOXOLONE year 2 data from cardinal trial expected in fourth quarter 2020 ENROLLMENT RESUMED IN falcon tRIAL PLANO, Texas—August 10, 2020 (GLOB |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37785 Reata Pharmaceuticals, Inc. |
|
| August 10, 2020 |
First Amendment to Lease Agreement, dated as of May 27, 2020. Exhibit 10.1 FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (this “Amendment”) is made and entered into as of this 27 day of May, 2020, by and between TC LEGACY PHASE I VENTURE, LLC, a Delaware limited liability company (“Landlord”), and REATA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). RECITALS A.Landlord and Tenant entered into a certain Lease Agreement |
|
| August 10, 2020 |
Fourth Amended and Restated Non-Employee Director Compensation Policy, dated as of June 10, 2020. Exhibit 10.4 REATA PHARMACEUTICALS, INC. FOURTH AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Reata Pharmaceuticals, Inc. (“Reata”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Fourth Amended and Res |
|
| August 10, 2020 |
Exhibit 10.2 Execution Version COMMON STOCK PURCHASE AGREEMENT BY AND BETWEEN REATA PHARMACEUTICALS, INC. AND BXLS V – River L.P. AND BXLS FAMILY INVESTMENT PARTNERSHIP (CYM) V- ESC L.P. Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in thi |
|
| July 31, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2020 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 31, 2020 |
Exhibit 99.1 REATA ANNOUNCES THE APPOINTMENT OF MARTIN W. EDWARDS, M.D. TO ITS BOARD OF DIRECTORS PLANO, Texas—July 30, 2020 (GLOBE NEWSWIRE)—Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointment of Martin W. Edwards, M.D. to its Board of Directors, effective August 3, 2020. Since 2003, Dr. Edwards |
|
| July 31, 2020 |
Exhibit 10.1 REATA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT This Agreement (“Agreement”) is made and entered into as of the 3rd day of August, 2020, by and between Reata Pharmaceuticals, a Delaware corporation (the “Company”), and Martin W. Edwards, M.D. (“Indemnitee”). RECITALS A. Highly competent and experienced persons are reluctant to serve corporations as directors, executive officers |
|
| July 7, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2020 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 7, 2020 |
Exhibit 99.1 Reata Announces promotion and New hires for key leadership roles PLANO, Texas—July 7, 2020 (GLOBE NEWSWIRE)—Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the expansion of its leadership team and the appointment of several experienced industry leaders to key management roles. Colin J. Meyer, MD |
|
| June 24, 2020 |
Exhibit 99.1 Reata PHARMACEUTICALS, Inc. CLOSES $350 Million strategic investment from blackstone life sciences PLANO, Texas, June 24, 2020—Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the receipt of $350 million related to the closing of its previously announced strategic investment from funds managed by Blackst |
|
| June 24, 2020 |
Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2020 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 (June 10, 2020) Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorpor |
|
| June 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 (June 10, 2020) Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorpor |
|
| June 11, 2020 |
Exhibit 99.1 REATA PHARMACEUTICALS, INC. AND BLACKSTONE LIFE SCIENCES ANNOUNCE $350 MILLION STRATEGIC INVESTMENT Financing will advance bardoxolone as the first potential therapy for Alport syndrome, as well as continue development for other rare and serious forms of chronic kidney disease Reata’s cash guidance updated: Runway extended through end of 2023 Reata to host conference call on June 11, |
|
| June 2, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2020 (June 1, 2020) Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporat |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37785 Reata Pharmaceuticals, Inc. |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 11, 2020 |
Exhibit 99.1 Reata pharmaceuticals, inc. announces FIRST quarter 2020 financial RESULTS and provides an update on development programs PLANO, Texas—May 11, 2020 (GLOBE NEWSWIRE)—Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020, and provided an update on th |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* REATA PHARMACEUTICALS INC (Name of Issuer) Common Stock (Title of Class of Securities) 75615P103 (CUSIP Number) March 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 26, 2020 |
As filed with the Securities and Exchange Commission on February 26, 2020 As filed with the Securities and Exchange Commission on February 26, 2020 Registration No. |
|
| February 19, 2020 |
Notice of Grant of Restricted Stock Units for employees. Exhibit 10.38 Date Notice of Grant of Restricted Stock Units (Employee) Award Details Name : Address : Employee ID : Award Amount : Grant ID :Date of Grant: Award Type : Vesting Schedule :Vesting Start Date :Vesting End Date :Expiration Date : Deadline to Accept : 30 days from grant notification Award Vesting Summary The Forfeiture Restrictions on the Restricted Stock Units granted pursuant to the |
|
| February 19, 2020 |
Exhibit 99.1 Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financials and ProvideS an Update on Development Programs Conference Call with Management Scheduled for Today, February 19, 2020, AT 4:30 PM EASTERN TIME PLANO, Texas—February 19, 2020—Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today an |
|
| February 19, 2020 |
Exhibit 10.41 REATA PHARMACEUTICALS, INC. THIRD AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Reata Pharmaceuticals, Inc. (“Reata”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Third Amended and Rest |
|
| February 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37785 Reata Pharmaceu |
|
| February 19, 2020 |
Description of Registrant’s Securities. Exhibit 4.3 DESCRIPTION OF CLASS A COMMON STOCK General Reata Pharmaceuticals, Inc. (“Reata,” “we,” or “our”) is incorporated in the state of Delaware. The rights of Reata’s stockholders are generally covered by Delaware law and our certificate of incorporation (“Certificate”) and bylaws (“Bylaws”) (each as amended and restated and in effect as of the date hereof). The terms of our common stock ar |
|
| February 19, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2020 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 19, 2020 |
Gateway Lease Expansion Agreement, dated December 12, 2019. Exhibit 10.39 LEASE AMENDMENT NO. 12 THIS LEASE AMENDMENT NO. 12 (this “Amendment”) is made and entered into effective as of December 12, 2019 (the “Effective Date”) by and between SDCO GATEWAY COMMERCE I & II, INC., a Delaware corporation (“Landlord”), and REATA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). Recitals: WHEREAS, by Lease dated with a Lease Reference Date as of May 25, 20 |
|
| February 19, 2020 |
Denbury Lease Expansion Agreement, dated December 12, 2019. Exhibit 10.40 AMENDMENT NO. 1 TO SUBLEASE AGREEMENT This Amendment No. 1 to Sublease Agreement (this “Amendment”) is executed as of December 12, 2019, between DENBURY ONSHORE, LLC, a Delaware limited liability company (“Denbury”), and REATA PHARMACEUTICALS, INC., a Delaware corporation (“Subtenant”). RECITALS: WHEREAS, Denbury and Subtenant have entered into a Sublease Agreement dated November 30, |
|
| February 12, 2020 |
RETA / Reata Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Reata Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 75615P103 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| January 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Reata Pharmaceutical (Name of Issuer) Common Stock (Title of Class of Securities) 75615P103 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| December 20, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2019 Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 20, 2019 |
RETA / Reata Pharmaceuticals, Inc. / ROSE WILLIAM - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 20, 2019 |
Lock-Up Agreement Reata Pharmaceuticals, Inc. Public Offering of Common Stock EX-7.4 Exhibit 7.4 Lock-Up Agreement Reata Pharmaceuticals, Inc. Public Offering of Common Stock The Representative(s) of the Underwriters Named in Schedule II to the Underwriting Agreement Ladies and Gentlemen: This letter, dated as of the date set forth on the signature page hereto, is being delivered to you in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”) be |
|
| November 20, 2019 |
Lock-Up Agreement Reata Pharmaceuticals, Inc. Public Offering of Common Stock EX-7.5 3 d836820dex75.htm EX-7.5 Exhibit 7.5 Lock-Up Agreement Reata Pharmaceuticals, Inc. Public Offering of Common Stock The Representative(s) of the Underwriters Named in Schedule II to the Underwriting Agreement Ladies and Gentlemen: This letter, dated as of the date set forth on the signature page hereto, is being delivered to you in connection with the proposed Underwriting Agreement (the “U |
|
| November 14, 2019 |
EX-1.1 Exhibit 1.1 Execution Version Reata Pharmaceuticals, Inc. 2,400,000 Shares Class A Common Stock ($0.001 par value per share) Underwriting Agreement New York, New York November 13, 2019 Citigroup Global Markets Inc. Jefferies LLC SVB Leerink LLC As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Jefferies LLC 52 |
|
| November 14, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2019 (November 13, 2019) Reata Pharmaceuticals, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-37785 11-3651945 (State or Other Jurisdiction of |
|
| November 14, 2019 |
Prospectus Supplement Table of Contents Filed Pursuant to Rule 424(b)(5) SEC File No. |
|
| November 12, 2019 |
SUBJECT TO COMPLETION, DATED NOVEMBER 12, 2019 Preliminary Prospectus Supplement Table of Contents Filed Pursuant to Rule 424(b)(5) SEC File No. |
|
| November 12, 2019 |
Exhibit 99.1 REATA PHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS Conference call with management scheduled for today, November 12, 2019 at 8:00 AM ET PLANO, Texas—November 12, 2019—Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced financial results for the t |
|
| November 12, 2019 |
Management call to discuss Positive topline pivotal Year 1 CARDINAL Data Exhibit 99. |
